Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127829 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
A Phase 1 study of Tumors, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT00127829 is a Phase 1 study of Tumors that has completed, run by AstraZeneca. The registered enrollment target is 66 participants, below the 196-participant average among 20 other Tumors trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00127829, a Phase 1 study of Tumors, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
Conditions Studied
Interventions
- DRUG Gefitinib
Study Locations (2)
California
- Research Site - Los Angeles
- Research Site - Palm Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127829
The ClinicalTrials.gov registry entry for NCT00127829 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 20 other Tumors trials with a reported enrollment target (66% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Gefitinib is the first listed.
NCT00127829 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00127829 about?
NCT00127829 is a clinical study titled "Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic". This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
What is the current status of trial NCT00127829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2005-07. Estimated completion is 2008-01.
What conditions does trial NCT00127829 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT00127829?
The interventions under investigation include: Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00127829?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00127829 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.